In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function | Zendy

Amelia Barilli | Zendy; Rossana Visigalli | Zendy; Roberto Sala | Zendy; Gian C. Gazzola | Zendy; Alessandro Parolari | Zendy; Elena Tremoli | Zendy; Sabrina Bonomini | Zendy; Alexandra Simon | Zendy; Ellen I. Closs | Zendy; Valeria Dall’Asta | Zendy; Ovidio Bussolati | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function

Author(s) -

Amelia Barilli,

Rossana Visigalli,

Roberto Sala,

Gian C. Gazzola,

Alessandro Parolari,

Elena Tremoli,

Sabrina Bonomini,

Alexandra Simon,

Ellen I. Closs,

Valeria Dall’Asta,

Ovidio Bussolati

Publication year - 2008

Publication title -

cardiovascular research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.774

H-Index - 219

eISSN - 1755-3245

pISSN - 0008-6363

DOI - 10.1093/cvr/cvn024

Subject(s) - mtorc2 , viability assay , microbiology and biotechnology , pi3k/akt/mtor pathway , mtorc1 , function (biology) , sirolimus , chemistry , cell , cancer research , biology , signal transduction , biochemistry

Drug-eluting stents are widely used to prevent restenosis but are associated with late endothelial damage. To understand the basis for this effect, we have studied the consequences of a prolonged incubation with rapamycin on the viability and functions of endothelial cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research